Weight management · Phase 3
SURMOUNT-1: weight change without diabetes
What was tested?
Tirzepatide versus placebo in adults with overweight or obesity, excluding diabetes. ↗
Registered primary question: Percentage weight change and the proportion losing at least 5% of baseline weight at week 72. ↗
What the reviewed report found
Journal year 2022 · Article summary reviewed 2026-08-19
Reported mean body-weight change at week 72 ranged from -15.0% to -20.9% across tirzepatide groups and was -3.1% with placebo. Gastrointestinal events were the most common adverse events, and discontinuation for adverse events was more frequent in the tirzepatide groups.↗
Keep in context: The selected report concerns the 72-week weight endpoints. Later follow-up reports require their own appraisal. ↗↗
Participants, design, limitations and sources
Registry snapshot
- Registry enrollment
- 2,539 · reported actual
- Registry status
- Completed
- Allocation and masking
- Randomized · Double
- Design
- Parallel
- Eligible ages
- 18 Years; maximum not specified
- Registry results
- Posted in this snapshot
Registry source ↗ · Updated 2025-07-24; retrieved 2026-09-20. Registry enrollment is not necessarily the analyzed sample in a publication. Posted registry results and published article results are separate.
SURMOUNT-1 obesity trial
- Design in the report
- A double-blind, randomized, placebo-controlled Phase 3 trial assessed body-weight change over 72 weeks.↗
- Participants in the report
- The trial randomized 2,539 adults with obesity, or overweight plus at least one weight-related complication, and excluded people with diabetes.↗
- Limitations
- The sponsor-funded trial used a dose-escalation period, excluded diabetes, and does not by itself establish outcomes after treatment stops or uncommon harms over longer periods.↗
This reading covers the article abstract and record metadata. Read its preserved Human Evidence Review →
How the study identity and sources were checked
Study context checked 2026-09-20. Existing article summaries keep their original review dates. This is a selected study reading, not a complete literature or full-text appraisal.
Registry
A Study of Tirzepatide (LY3298176) in Participants With Obesity or Overweight ↗
Protocol identifier: 17244. Sponsor: Eli Lilly and Company.
Retrieved 2026-09-20; SHA-256 e31f19831be6c14f1bf3db3010afda083232090fc1fed493a9f83177c326f7de.
PMID 35658024
Tirzepatide Once Weekly for the Treatment of Obesity ↗
Exact trial identity is declared in PubMed’s ClinicalTrials.gov databank field. The registry independently labels this reference DERIVED. These source labels do not establish that every result in a paper applies to this trial.
Identity metadata retrieved 2026-09-20. EFetch batch XML; locate MedlineCitation/PMID 35658024. SHA-256 f2177628b98083064df17512c3dd229b760887c00cc64c4cfa4fc4e49523b12a.
Scientific summary uses the original 2026-08-19 source snapshot: SHA-256 f9a0b5da75a39caf7fb0ec78c5ca8b51a7e6169ea325c39a631aea907b2ccc37.